The most expensive therapies and drugs in the world

These therapies and treatments are sold at very high prices. In fact, their prices are so exorbitant that they pose a challenge not only to patients but also to the healthcare system and insurance companies, according to Scientific American magazine.

Skysona is a gene therapy treatment with a one-time cost of $3 million that slows the progression of cerebral adrenocorticotropic leukocytosis (CALD).

Some of the world's most expensive therapies and medications include:

Skysona

Skysona is a groundbreaking gene therapy with a single treatment costing $3 million USD, approximately 73 billion VND. Developed by the biotechnology company Bluebird Bio (USA), this therapy slows the progression of cerebral adrenocorticotropic leukoplakia (CALD).

CALD is a rare genetic disorder affecting the nervous system. Skysona therapy modifies the patient's stem cells to introduce the ALDP gene. This slows disease progression and improves the quality of life for those affected. The high cost of this therapy is due to the expenses involved in research, development, and production.

Zynteglo

Zynteglo is a lentivirus vector gene therapy also developed by Bluebird Bio. The cost of this therapy is up to $2.8 million USD, approximately 68 billion VND, per treatment. The drug is intended for patients with transfusion-dependent thalassemia (TDT), a rare blood disorder that requires patients to receive regular, lifelong blood transfusions to survive.

Zynteglo therapy will help reduce, or even eliminate, the need for blood transfusions, thereby improving quality of life as well as the physical and financial burden of blood transfusions.

Zolgensma

Zolgensma is considered a revolutionary gene therapy for treating spinal muscular atrophy (SMA), a rare genetic disorder in children. The drug was developed by Novartis (Switzerland) and approved by the U.S. Food and Drug Administration (FDA) in May 2019.

The average cost of this treatment is $2.1 million, approximately 50 billion VND. Zolgensma works by replacing faulty or missing genes in survival motor neurons 1 (SMN1). This abnormality is the cause of the disease.

Zokinvy

Zokinvy is used to treat Hutchinson-Gilford progeria syndrome (HGPS) and progeroid laminopathies. These are extremely rare genetic diseases that cause premature aging in children.

Zokinvy was developed by the biotechnology company Eiger BioPharmaceuticals (USA). The cost of treatment with this therapy is $1.7 million per year, approximately 25 billion VND. The drug is taken orally and works to delay disease progression and improve the quality of life for pediatric patients, according to Scientific American.

Source link: https://thanhnien.vn/nhung-lieu-phap-thuoc-dieu-tri-dat-nhat-the-gioi-185240105003114282.htm